<DOC>
	<DOCNO>NCT00054873</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety tezacitabine give alone combination 5-fluorouracil ( 5-FU ) subject advance esophageal gastric adenocarcinoma .</brief_summary>
	<brief_title>Tezacitabine With Without 5-Fluorouracil ( 5-FU ) Advanced Esophageal Cancer Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Tezacitabine</mesh_term>
	<criteria>Males female great equal 18 year age . Histologically confirm recurrent ( inoperable ) metastatic adenocarcinoma esophagus , gastroesophageal junction , stomach . At least one bidimensionally measurable lesion , previously irradiate , diameter meet RECIST criterion , serially measure . Intraluminal tumor , evaluable endoscopy , acceptable target lesion . Karnofsky Performance Score great equal 70 % . Subjects must second line therapy setting , thus must experience progression follow treatment one ( one ) prior chemotherapy regimen use treatment unresectable locally advanced , recurrent , metastatic disease . Recovery serious ( grade 3 high ) toxic effect prior radiation therapy . Adequate hematologic profile : absolute neutrophil count great equal 1,500/mm3 ; hemoglobin great equal 9 g/dL ; hematocrit great equal 30 % ( transfusion allow ) ; platelet count great equal 100,000/mm3 . Adequate hepatic function : bilirubin le equal 1.5 mg/dL ; AST ALT le 2.5 X ULN ( 5 X ULN liver involve tumor ) ; alkaline phosphatase le 5 X ULN Adequate renal function ; serum creatinine less equal 1.5 mg/dL calculate creatinine clearance great 50 mL/min . Both male female subject childbearing potential must use contraceptive method medically acceptable investigative center . Diseasefree prior malignancy , nonmelanoma skin cancer carcinoma insitu cervix , great 5 year . Unstable angina class III IV New York Heart Association heart disease . CNS metastases . Pregnant breastfeeding . Uncontrolled seizure disorder . Ongoing ( grade 3 high ) stomatitis , esophagopharyngitis , uncontrolled diarrhea . Impaired nutritional status evidence serum albumin 2.7 mg/dL less . Major surgery , chemotherapy , immunotherapy , radiotherapy 28 day precede first study treatment . Concomitant anticancer therapy ( chemotherapy , immunotherapy , radiation ) investigational agent study participation 28 day prior study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Adenocarcinoma esophagus stomach</keyword>
</DOC>